<DOC>
	<DOCNO>NCT02284607</DOCNO>
	<brief_summary>This Phase 1 , randomize , double-blind , placebo-controlled study evaluate safety , tolerability pharmacokinetics two , single intravenous ( IV ) high dos MHAA4549A compare placebo administer healthy volunteer .</brief_summary>
	<brief_title>A Study High Dose MHAA4549A Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Age 18 year old Body mass index ( BMI ) 18 32 kg/m2 , inclusive Weight 40 100 kg In good health , determine clinically significant finding medical history , 12lead ECG , vital sign , clinical laboratory evaluation Willing use acceptable contraceptive measure define protocol Agreeable , deem able investigator , comply requirement study , include followup period Willing abstain use drug abuse enrol study History clinically significant manifestation disorder History acute allergic reaction drug allergy History presence abnormal ECG History significant alcohol abuse within 1 year prior screen regular use alcohol within 6 month prior screen visit History significant drug abuse within 1 year prior screen Current tobacco smoker Positive drug screen screen checkin Positive pregnancy test result screen Day 1 breast feeding study Males pregnant female partner Donation plasma within 7 day prior study drug administration Donation loss whole blood Receipt blood product within 2 month initiation dose Day 1 History malignancy within 10 year screen except completely excise basal cell carcinoma squamous cell carcinoma skin History severe systemic bacterial , fungal , parasitic infection associate two hospitalization per year two course intravenous ( IV ) antibiotic within 1 year Received oral antibiotic within 4 week initiation dose Day 1 , IV antibiotic within 8 week initiation dose Hospitalization within 4 week initiation dose Day 1 Use counter prescription medications/products within 7 day prior Day 1 unwilling abstain use drug least Day 29 study visit , unless deem acceptable investigator Sponsor Participation clinical trial within 4 week Received vaccine within 14 day prior screen Positive blood test chronic viral infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>